Company: XAIR
Filing Date: 2025-11-10
Form Type: 10-Q
Source: 0001493152-25-021561
Chunk: 8

Company: Beyond Air, Inc.
Filing Date: 2025-11-10
Form: 10-Q
Item: Part I, Item 1
Chunk 8
---

    activities 
    $12,984  
    $21,360 

    Effect of exchange rate
    changes on cash and cash equivalents 
     145  
     (23)

    Increase in cash, cash equivalents and restricted
    cash 
    $4,966  
    $17,069 
  
    Cash, cash equivalents
    and restricted cash at beginning of period 
     4,896  
     11,608 
  
    Cash, cash equivalents
    and restricted cash at end of period 
    $9,862  
    $28,677 
  
    Supplemental disclosure of non-cash investing
    and financing activities 

    Debt discount 
    $-  
    $853 
  
    End of term loan liability 
    $-  
    $(138)
  
    Warrant liability 
    $-  
    $(214)
  
    Derivative liability 
    $-  
    $(1,314)
  
    Right-of-use assets 
    $-  
    $(309)
  
    Operating lease liability 
    $-  
    $(309)
  
    Cash receivable as part of Securities Purchase
    Agreement II 
    $-  
    $370 

    Supplemental disclosure of cash flow items: 

    Interest paid 
    $195  
    $1,110 
  
    Income taxes paid 
    $-  
    $- 

The
accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

8

BEYOND
AIR, INC. AND SUBSIDIARIES

NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

NOTE
1 ORGANIZATION AND BUSINESS

Beyond
Air, Inc. (together with its subsidiaries, “Beyond Air” or the “Company”) was incorporated on April 28, 2015
under Delaware law. On June 25, 2019, the Company’s name was changed to Beyond Air, Inc. from AIT Therapeutics, Inc.

The
Company is a commercial-stage medical device and biopharmaceutical company developing a platform of nitric oxide (“NO”) generators
and delivery systems (the “LungFit® platform”) capable of generating NO from ambient air. The Company’s
first device, LungFit® PH (“LungFit® PH”) received premarket approval (“PMA”) from
the